



New antivirals and strategy to evaluate candidates for COVID 19 Treatment (AGILE)

Saye Khoo




Disclosures and Funding

Disclosure & Funding Statement

- *The AGILE Platform is funded by the Wellcome Trust, the UK Medical Research Council, and UKRI*
- *AGILE trials have received support from Unitaid, Ridgeback Biotherapeutics, GSK and Vir Biotechnology*
- *Infrastructure support from NIHR, CRUK*
- *SK has received funding from ViiV, Gilead, Merck unrelated to this work*
- *A full transparency statement is available on www.agiletrial.net/*



COVID-19 : Clinical Progression of Disease



Vaccine

Prophylaxis

Antivirals




Host Directed Therapies

New Antiviral Treatments for COVID -19

The Problem:

- **‘Conventional’ drug development not designed for pandemic**
 - *too slow*
 - *not responsive to changes in clinical care, viral evolution, population immunity*
 - *initial candidates in Phase III without sufficient level of supportive evidence*
- **Need for new (antiviral) compounds**
 - *‘repurposing’ always going to be a stopgap*
- **Research in a very challenging environment**
 - *facilities, staff, environment, infection control, public health*
 - *each study carries opportunity costs*

Case Fatality Rates have fallen




Source: Johns Hopkins University CSSE COVID-19 Data - Last updated 15 January, 09:05 (London time)


Note: Only countries with more than 100 confirmed cases are included. Only countries with more than 100 confirmed cases are included.

Powered by ourworldindata.org


SARS CoV-2 Diversity and Evolution of the Pandemic



SARS CoV-2 Diversity and Evolution of the Pandemic




Antiviral Therapy – potential targets





mAbs and Ab-like molecules




Monoclonal Antibodies – not all the same

- Binding sites
- Neutralising activity
- Breadth
- Resistance in VOCs
- Antibody-dependent cellular cytotoxicity
- Pharmacology



<https://www.antibodysociety.org/covid-19-biologics-tracker>





Planas et al
Nature: 23 December 2021

mAbs and Ab-like molecules

Monoclonal Antibodies

Ab- like molecules



- IgY (egg-yolk immunoglobulin)
- Camelid antibodies /nanobodies (15-75k kDa)
- DARPs (designed ankyrin repeat protein)
- others

Ensovibep

- 'designed ankyrin repeat protein', or DARPin
- designed to bind to three different locations on spike protein
- prevent the virus from infecting human cells

EMPATHY (Phase 2/3)

- Phase 2 (N=407) - significant VL reduction over 8d at 75mg, 225mg and 600mg
- Hospitalisations/ER visits 6/99 (6%) controls vs 4/301 (1.3%) ensovibep
- Phase 3 in progress (75mg)



Small Molecules

Directly Acting Antivirals

- Remdesivir (iv) and GS-441524 (o)
- Molnupiravir
- Favipiravir
- Nirmatrelvir/r (Paxlovid)
- S-217622
- AT-527

www.covid19-druginteractions.org



COVID-19 Drug Interactions



UNIVERSITY OF
LIVERPOOL

	Molnupiravir [Lagevrio]	Nirmatrelvir/ritonavir [Paxlovid] (Please read the interaction details as management of these interactions may be complex.)	Remdesivir [Veklury]	Sotrovimab [Xevudy]	Tixagevimab/ Cilgavimab [Evusheld]
Acenocoumarol	◆	■	◆	◆	◆
Apixaban	◆	●	◆	◆	◆
Argatroban	◆	◆	◆	◆	◆
Aspirin (Anti-platelet)	◆	◆	◆	◆	◆
Betrixaban	◆	■	◆	◆	◆
Clopidogrel	◆	●	◆	◆	◆
Dabigatran	◆	■	◆	◆	◆

www.covid19-druginteractions.org



COVID-19 Drug Interactions



UNIVERSITY OF
LIVERPOOL

	Molnupiravir [Lagevrio]	Nirmatrelvir/ritonavir [Paxlovid] (Please read the interaction details as management of these interactions)	Remdesivir [Veklury]	Sotrovimab [Xevudy]	Tixagevimab/ Cilgavimab [Evusheld]
Olanzapine	◆	◆	◆	◆	◆
Paliperidone	◆	▲	◆	◆	◆
Perazine	◆	■	◆	◆	◆
Periciazine	◆	◆	◆	◆	◆
Perphenazine	◆	▲	◆	◆	◆
Pimozide	◆	●	◆	◆	◆
Pipotiazine	◆	◆	◆	◆	◆
Quetiapine	◆	●	◆	◆	◆
Risperidone	◆	■	◆	◆	◆

www.covid19-druginteractions.org





COVID-19 Drug Interactions







UNIVERSITY OF
LIVERPOOL

	Molnupiravir [Lagevrio]	Nirmatrelvir/ritonavir [Paxlovid] (Please read the interaction details as management of these interactions may be complex.)	Remdesivir [Veklury]	Sotrovimab [Xevudy]	Tixagevimab/ Cilgavimab [Evusheld]
Amiodarone	◆	●	◆	◆	◆
Bepridil	◆	●	◆	◆	◆
Digoxin	◆	■	◆	◆	◆
Disopyramide	◆	●	◆	◆	◆
Dofetilide	◆	●	◆	◆	◆
Flecainide	◆	●	◆	◆	◆
Lidocaine (Lignocaine)	◆	■	◆	◆	◆
Mexiletine	◆	■	◆	◆	◆
Propafenone	◆	●	◆	◆	◆
Quinidine	◆	●	◆	◆	◆




Early-phase drug development:

- **Fast-track** promising candidates
- **Screen-out** compounds with limited potential
- **Accelerate** decision-making
- Seamlessly **transition** between phases
- Test **multiple** candidates at once



RECOVERY
Randomised Evaluation of COVID-19 Therapy


PRINCIPLE
Platform Randomised trial of Interventions against COVID-19 in older people




Multi-arm, multi-stage, adaptive Bayesian platform trial
Community or hospital
Antiviral or host targets

- **Pragmatic** FIH in COVID patients
- **Flexible** endpoints tailored to drug action
- **Seamless** population tailored to expected deployment
- **Efficient** phase I → II
- Bayesian approach to decision-making


agile
Coronavirus Drug Testing Initiative




Basket trial



Umbrella trial



Platform trial



Flexibility to

- Drop arms
- Introduce new arms
- Re-estimate N within an arm
- Response adaptive randomization – adapt allocation ratio
- Share controls (with caveats)
- Enrich subgroups of particular interest
- etc

ANTICOV

RECOVERY

Randomised Evaluation of COVID-19 Therapy

COMBATCOVID

OTAC
INSIGHT012

ACTIV-4

PRINCIPLE
Platform Randomised trial of Interventions
against COVID-19 In older peoPLE

REMAP-CAP

ACTIV-6

ACTIV-1 IM
Randomized Master Protocol for
Immune Modulators for Treating COVID-19




PANORAMIC

Platform Adaptive trial of NOvel
antiVirals for eArly treatMent of
COVID-19 In the Community

together • COVID-19
clinical trials

SOLIDARITY TRIAL PLUS



How the Bayesian Model Works

- Efficient use of Information
- **Accelerates Decision-Making**




Establishing Safe Dose (Phase I)

- Prior is set to maximise probability of accurate dose selection for phase II
- Borrows information across doses
- Dose-limiting toxicities: Dose is **unsafe if $\geq 25\%$ chance that treatment gives $\geq 30\%$ higher DLTs** over controls
- **Next dosing tier set as closest to a 20% (tolerance 15-25%) increase in DLT**
- Next dosing tier no more than double last dosing tier

How the Bayesian Model Works


Prior Distribution on Each Dose



Dose-Toxicity Model

$$\text{logit} p_j = \theta_1 + \theta_2 \tilde{d}_j$$



- \tilde{d}_j are the standardized dose levels
- θ_1 (intercept), θ_2 (slope) are (continuously updated) parameters;



How the Bayesian Model Works

Prior Distribution on 600bd

Posterior Distribution on 600bd



Case Study - Molnupiravir

Cohort 1 – 300mg bd

Dose-Toxicity Plot (7 day data only)




Figure 1: Dose-toxicity plot based on seven-day data only

Cohort 2 – 600 mg bd

Dose-Toxicity Plot (7 day data only)




Figure 5.1: Dose-toxicity plot based on seven-day data only

Cohort 3 800mg bd

Dose-Toxicity Plot (7 day data only)




Figure 5.1: Dose-toxicity plot based on seven-day data only

How the Bayesian Model Works


- Efficient use of Information
- Accelerates Decision-Making



Establishing Early Efficacy (Phase IIa)

- HR over control or placebo (e.g. virological response)
- **FUTILITY** if probability of HR >1 is <33%
- **EFFICACY** if probability HR >1 is >80%
- Interim evaluation

AGILE - Portfolio



Press release

Groundbreaking COVID-19 treatments to be fast-tracked through clinical trials

The world's most innovative treatments for COVID-19 will soon be fast-tracked through the UK's clinical trial system, as the government announces funding for the most promising treatments.

From: [Department of Health and Social Care](#)

Published 13 February 2021

AGILE CST-2 (molnupiravir)

- Phase Ib completed – dose optimized
- Phase IIa recruiting

AGILE CST-3 (high-dose nitazoxanide)

- Phase Ia completed – dose optimized
- Phase Ib/IIa under regulatory assessment (S Africa)

AGILE CST-5 (GSK/Vir 7832 monoclonal antibody)

- Phase I recruiting (FIH cycle 3)

IN DEVELOPMENT

Conclusions

- **COVID has accelerated use of Master Protocols and Platform Trials**
- **Coupled with statistically efficient methods to offer flexibility, responsiveness, and accelerated decision making**
- **Could be applied to LMIC settings**
- **A vital tool for medical countermeasures during PH emergencies**




Saye Khoo
 Andrew Owen
 Helen Reynolds
 Bill Greenhalf
 Julian Hiscox
 Tori Shaw
 Laura Else
 Justin Chiong
 Michelle Tetlow



Liverpool CRF

Richard Fitzgerald
 Lauren Walker
 Rebecca Lyon
 Christie Woods
 Marcin Bula



National Institute for Health Research

NIHR CRFs

Manchester
 Southampton
 Preston
 London



Tom Fletcher
 David Laloo
 Michael Jacobs



Thomas Jaki
 Pavel Mozgunov



Southampton Clinical Trials Unit

Gareth Griffith
 Sean Ewings
 Geoff Saunders
 Andrea Corkhill
 Nicky Downs
 Emma Knox
 Anna Song
 et al



Infectious Diseases Institute

Shevin Jacob
 Mohamed Lamorde



University of Cape Town

Catherine Orrell



WITS RHI

Francois Venter